DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Expected to Earn Q3 2024 Earnings of ($0.13) Per Share

by · The Cerbat Gem

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Free Report) – Stock analysts at HC Wainwright issued their Q3 2024 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Monday, October 7th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at ($0.47) EPS.

Separately, Oppenheimer reissued an “outperform” rating and set a $6.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, August 16th.

Read Our Latest Research Report on DiaMedica Therapeutics

DiaMedica Therapeutics Price Performance

Shares of DiaMedica Therapeutics stock opened at $4.42 on Wednesday. The stock has a market capitalization of $188.92 million, a price-to-earnings ratio of -7.89 and a beta of 1.48. The business has a 50-day moving average of $3.99 and a 200 day moving average of $3.27. DiaMedica Therapeutics has a 12 month low of $1.94 and a 12 month high of $4.95.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period in the previous year, the business earned ($0.16) EPS.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors have recently bought and sold shares of DMAC. Magnolia Capital Advisors LLC acquired a new stake in DiaMedica Therapeutics during the 2nd quarter worth $87,000. Vanguard Group Inc. lifted its position in DiaMedica Therapeutics by 26.3% during the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after acquiring an additional 211,351 shares during the period. Finally, Paragon Associates & Paragon Associates II Joint Venture grew its position in DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after buying an additional 30,000 shares during the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

Read More